Cangene Corp. received approval from the Ontario Superior Court of Justice for the previously announced acquisition of Cangene by Emergent BioSolutions, Inc. Under the court-approved Plan of Arrangement, Cangene shareholders will receive $3.24 per share in cash, for an aggregate purchase price of $222 million.
The transaction, subject to additional customary closing conditions, is expected to close in February 2014.
Cangene Acquisition Gets Ontario Court Approval
By Kristin Brooks
Published February 19, 2014
blog comments powered by Disqus